MINIMUM bio has developed a versatile, high throughput discovery technology with broad applications in the development of new therapeutic products and the repositioning of existing drugs. The Company’s expertise and know-how is based on our phage display technology platform that permits us to rapidly identify proteins that bind to bioactive molecules of interest. The Company has repurposed an antibody drug discovery platform (phage display) and repurposed it for drug target discovery and believes that this platform is a powerful method that can also be used to identify protein targets of small molecules, biologics and molecular glues, and has significant advantages over conventional and mass spectrometry-based approaches. Advantages include: increased speed, less background and less bias toward common, high-abundance, but low affinity targets. Over the past 15 years we have been improving and refining the phage display technique (‘Mercurious®’) to the point where we can now rapidly screen for protein binding partner(s) for any small molecule, natural product, biologic or molecular glue.

MINIMUM bio is pursuing a partnership strategy with large and small Pharma to develop and stress-test its target discovery platform and is developing its own strategy for the rapid and discovery of non-degrader molecular glues.

The Company’s Mercurious platform generally consists of: (i) generating a Phage Display library; (ii) screening the library and separating phages that display proteins or protein domains that bind to the molecule of interest; and (iii) sequencing the DNA inside individual phage or phage populations to identify the binding protein or motif.

The Mercurious platform can also be used to:

• Deconvolute Phenotypic Screening Results
• Drug Repositioning
• New Target Identification
• Real/Alternative Target Identification
• Off-Target Identification

Watch our informative video.

Please see our company profile at the Australian Biodirectory